The drug has been shown to be effective and feasible in treating patients with NTRK‐rearranged solid tumors and advanced ROS1 rearranged NSCLC, in an integrated analysis of relevant clinical trials.8, 9. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.